Categories
Archives
- 2026
- 2025
- 2024
- 2023
Oct
15
Powering the dreams of people impacted by myasthenia gravis (MG)
Oct
15
UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.
Oct
14
UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)
Oct
11
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
Sep
23
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Sep
23
Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community
Sep
09
TK2d Awareness Day: The complexity of this rare, genetic mitochondrial disease and its impact on daily living can no longer be overlooked
Sep
05
The Legacy Continues: Celebrating Two Decades of the UCB Family Epilepsy Scholarship ProgramTM
Aug
21
From Homework to Holidays: How Families Living with Epilepsy Can Prepare for Seasonal Changes
